Department of Neurology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Department of Neurology, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Brain Res Bull. 2020 May;158:122-127. doi: 10.1016/j.brainresbull.2020.03.009. Epub 2020 Mar 9.
Recent studies have suggested that specific plasma ceramides are independently associated with atherosclerosis and cardiovascular diseases, but it is currently unknown whether plasma ceramide levels are associated with ischemic stroke. Here, we examined whether ceramides were associated with both ischemic stroke risk and clinical severity at admission. We measured three previously identified high-risk plasma ceramide molecules [Cer(d18:1/16:0), Cer(d18:1/22:0), and Cer(d18:1/24:0)] in 202 patients with acute ischemic stroke and 202 age and sex matched control cases. Plasma ceramides levels were measured by a targeted liquid chromatography-tandem mass spectrometry assay at baseline. The median age of the 202 stroke patients was 66 (interquartile range [IQR], 58-75) years and 54.0 % were men. Plasma levels of C16:0, C22:0, and C24:0 ceramides in stroke patients were significantly higher than in those control cases (P < 0.001, all). In multivariate logistic regression analysis adjusted for other risk factors, higher levels of C16:0, C22:0, and C24:0 ceramides were associated with higher risk of ischemic stroke (odd ratio [OR] for one IQR increase: 2.15[1.42-2.99]; 2.90[2.13-4.01] and 1.29[1.10-1.69]; respectively). At admission, 103 patients (51.0 %) had a minor stroke (NIHSS < 6). In these patients, plasma levels of C16:0, C22:0, and C24:0 ceramides were lower than that observed in patients with moderate-to-high clinical severity (P < 0.001, all). In multivariate logistic regression analysis adjusted for other risk factors, higher levels of C16:0, C22:0, and C24:0 ceramides were associated with higher risk of moderate-to-high stroke (OR for one IQR increase: 2.96 [2.05-4.22], 3.03 [2.01-4.25] and 1.72 [1.25-3.31], respectively). An elevated plasma levels of ceramides were predictors of both risk and severity at admission in ischemic stroke patients. The underlying mechanisms of these associations remain to be investigated.
最近的研究表明，特定的血浆神经酰胺与动脉粥样硬化和心血管疾病独立相关，但目前尚不清楚血浆神经酰胺水平是否与缺血性中风有关。在这里，我们研究了神经酰胺是否与缺血性中风风险和入院时的临床严重程度有关。我们在 202 名急性缺血性中风患者和 202 名年龄和性别匹配的对照组中测量了三种先前确定的高风险血浆神经酰胺分子[Cer(d18:1/16:0)、Cer(d18:1/22:0)和 Cer(d18:1/24:0)]。在基线时通过靶向液相色谱-串联质谱法测定血浆神经酰胺水平。202 名中风患者的中位年龄为 66(四分位间距[IQR]，58-75)岁，54.0%为男性。中风患者的 C16:0、C22:0 和 C24:0 神经酰胺水平明显高于对照组(P<0.001，均)。在调整其他危险因素的多变量逻辑回归分析中，较高水平的 C16:0、C22:0 和 C24:0 神经酰胺与缺血性中风的风险增加相关(一个 IQR 增加的比值比[OR]：2.15[1.42-2.99];2.90[2.13-4.01]和 1.29[1.10-1.69];分别)。入院时，103 名患者(51.0%)为轻度中风(NIHSS<6)。在这些患者中，C16:0、C22:0 和 C24:0 神经酰胺的血浆水平低于中重度临床严重程度患者观察到的水平(P<0.001，均)。在调整其他危险因素的多变量逻辑回归分析中，较高水平的 C16:0、C22:0 和 C24:0 神经酰胺与中重度中风的风险增加相关(一个 IQR 增加的比值比[OR]：2.96[2.05-4.22]、3.03[2.01-4.25]和 1.72[1.25-3.31]，分别)。升高的血浆神经酰胺水平是缺血性中风患者入院时风险和严重程度的预测因子。这些关联的潜在机制仍有待研究。
